New hope for Huntington's patients: drug eases involuntary movements
NCT ID NCT07601516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well and how safely deutetrabenazine works for Chinese adults with Huntington's disease who have chorea (uncontrolled movements). Fifty patients took the drug as part of their normal care. The main goal was to see if chorea scores improved, especially in those taking at least 24 mg daily. The study also tracked side effects and serious events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOREA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Teva Investigational Site 01
Chengdu, 610041, China
-
Teva Investigational Site 02
Beijing, 100070, China
-
Teva Investigational Site 03
Beijing, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scan tracer could reveal hidden signs of psychosis in Parkinson's
- Hope for Huntington's: new drug aims to slow decline in major trial
- Experimental drug aims to curb disinhibition in dementia patients
- New drug SRP-1005 takes first step against Huntington's
- Global brain surgery matchmaker aims to help kids with rare movement disorders
- Can video games help Huntington's patients move and think better?